ERRATUM

Erratum: Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin

Aaron U. Blackham, MD¹, Perry Shen, MD¹, John H. Stewart, MD¹, Gregory B. Russell, MS², and Edward A. Levine, MD¹

¹Surgical Oncology Service, Wake Forest University Baptist Medical Center, Winston-Salem, NC; ²Departments of General Surgery and Public Health Sciences, Wake Forest University Baptist Medical Center, Winston-Salem, NC

ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-010-1080-6

The article by Blackham et al., “Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin” (DOI [10.1245/s10434-010-1080-6](https://doi.org/10.1245/s10434-010-1080-6)) contained two errors: In Figure 4, the Kaplan–Meier curve for overall survival in the cisplatin cohort was omitted. Secondly, in Table 3, the *P*-value for median survival (0.22) was misprinted under 4-year survival.

Below the correct figure and table are now published.

FIG. 4 Kaplan–Meier curve for overall survival of 34 patients with malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy separated by chemoperfusate (*P* = 0.22)

The online version of the original article can be found under doi:[10.1245/s10434-010-1080-6](https://doi.org/10.1245/s10434-010-1080-6).

© Society of Surgical Oncology 2010

Published Online: 21 December 2010

E. A. Levine, MD
e-mail: elevine@wfubmc.edu

TABLE 3 Survival analysis of 34 patients with malignant peritoneal mesothelioma who underwent cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin or cisplatin

	Overall <i>n</i> = 34	Mitomycin <i>n</i> = 19	Cisplatin <i>n</i> = 15	<i>P</i> -Value
Survival				
1 year	61%	47%	80%	0.05
2 year	61%	47%	80%	0.05
3 year	56%	42%	80%	0.04
4 year	28%	26%	n/a ^a	
5 year	17%	16%		
Median survival (months)	40.8	10.8	40.8 ^b	0.22
Survival range (months)	0.3–174+	0.3–174+	3.1–44.2	

“+” signifies patient(s) is still alive

^a No patient has been followed longer than 44.2 months

^b Estimated, because true median survival has not been reached yet